Introduction
Thrombotic thrombocytopenic purpura (TTP) is characterized clinically by thrombocytopenia, microangiopathic haemolytic anaemia, fever, fluctuating neurologic signs and renal dysfunction. Histology shows diffuse thrombotic occlusions in which platelets and fibrin are found (Amorosi and Ultmann, 1966) . The complexity of these clinical findings have led to speculation that TTP is a syndrome of diverse aetiologies (Umlas and Kaiser, 1970) . The outcome is almost invariably fatal and since pathogenesis remains ill-understood, many therapeutic regimens have been employed with undefined success. Among these, five are particularly advocated. Splenectomy (Bernard, Bonman and Schwartz, 1969) , antiplatelet agents (Amir and Kraus, 1973) , high doses of glucocorticoids (Burke and Hartman, 1959) , exchange transfusions (Bukowski et al., 1976) and plasmapheresis (Bukowski, King and Hewlett, 1977 transfused on this occasion. The dose of prednisolone was increased to 100 mg/day over the next 2 days and then rapidly diminished for the following 5 days. The benefit was immediate; the pain ceased, the platelet count increased to 290 x 109/1 and remained such despite the rapid reduction in the steroid dosage.
By the time of discharge, all manifestations of TTP and its complications had resolved and the patient was in a sustained remission. She had received a total of 50 units of FFP.
The patient has been followed as an out-patient for a period of two years. On three occasions she has developed bouts of abdominal pain with a drop in the thrombocyte count. During these episodes she received plasma transfusions on each occasion and improved. Now, two years subsequent to discharge she remains well, free of complaints and with a normal haematological picture.
Discussion
Despite the lack of histological evidence, our patient exhibited all the characteristic clinical features of TTP. Furthermore, there were also ample clinical grounds for a diagnosis of SLE.
Considerable overlap between SLE and TTP on both clinical (Amorosi et al., 1966) and anatomical grounds (Levine and Shearn, 1964 ) is known to exist.
In a review of 151 cases of TTP (Levine and Shearn, 1964 ) the additional presumptive diagnosis of SLE was made in 34 of these patients.
The pathogenesis of TTP is still unknown. The (Bukowski et al., 1976 (Bukowski et al., , 1977 . The mechanism for the effectiveness of these procedures was thought to be related to removal of an initiating or damaging agent, possibly immune complexes.
However, the observation that the disorder can be successfully treated by simple plasma infusions raised new questions concerning the pathogenesis and treatment of this disease. Until now, we are aware of 12 other patients with TTP that have been treated by plasma infusion and in 10 of them the treatment was highly effective (Byrnes and Lian, 1979) . In three of these patients, plasma collected during relapse induced, in vitro, aggregation of washed platelets from both normal donors and patients during remission. It was thus postulated that TTP appears to be due to a deficiency of a plasma inhibitor that counteracts a platelet aggregating factor present in normal and TTP plasma. In another patient, the disease was exacerbated during plasmapheresis when albumin-saline was used for volume replacement, and the manifestations remitted with subsequent whole blood exchange transfusions (Reiss et al., 1978) .
Whatever the exact mechanism, it is apparent that TTP is most frequently responsive to replacement of a plasma factor and the effectiveness of exchange transfusion and plasmapheresis is due to replaced plasma and not the removal of an unknown factor, toxin or immune complexes from the circulation (Byrnes and Lian, 1979) .
The clinical course and the rapid improvement observed in our patient is in accord with similar cases where plasma infusions were successfully used. Although it is impossible to state that she failed to respond to the high dose of corticosteroids it appeared that the plasma infusions resulted in the dramatic change in the clinical course of the patient. The post-hospitalization occurrence of several at-.tacks of abdominal pain associated with thrombocytopenia which responded to plasma infusions alone gives added credence to our assumption regarding the therapeutic efficacy of this mode of treatment in this patient. Nalbadian, Henry and Rich (1979) have stated that plasma infusion is the most important therapeutic innovation in the history of TTP. To date, insufficient experience with this form of treatment exists for specific guidelines for the use of plasma to be established. There is no doubt, however, that this therapeutic approach raises the most hope for the very ill patient with TTP. 
